Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance

被引：76

作者：

Lovly, Christine M. ^{[2
]}

Pao, William ^{[1
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Div Hematol & Oncol, Dept Med, Nashville, TN 37232 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2012年 / 4卷 / 120期

关键词：

ACTIVATING MUTATIONS; ONCOGENIC MUTATIONS; KINASE INHIBITOR; LUNG-CANCER; IDENTIFICATION; CRIZOTINIB; FUSION; GENE; RECEPTOR;

D O I：

10.1126/scitranslmed.3003728

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.

引用

页数：5

共 31 条

[1] Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma [J].

Bresler, Scott C. ;

Wood, Andrew C. ;

Haglund, Elizabeth A. ;

Courtright, Joshua ;

Belcastro, Lili T. ;

Plegaria, Jefferson S. ;

Cole, Kristina ;

Toporovskaya, Yana ;

Zhao, Huaqing ;

Carpenter, Erica L. ;

Christensen, James G. ;

Maris, John M. ;

Lemmon, Mark A. ;

Mosse, Yael P. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (108)

[2] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor [J].

Butrynski, James E. ;

D'Adamo, David R. ;

Hornick, Jason L. ;

Dal Cin, Paola ;

Antonescu, Cristina R. ;

Jhanwar, Suresh C. ;

Ladanyi, Marc ;

Capelletti, Marzia ;

Rodig, Scott J. ;

Ramaiya, Nikhil ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Wilner, Keith D. ;

Christensen, James G. ;

Jaenne, Pasi A. ;

Maki, Robert G. ;

Demetri, George D. ;

Shapiro, Geoffrey I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1727-1733

[3] Oncogenic mutations of ALK kinase in neuroblastoma [J].

Chen, Yuyan ;

Takita, Junko ;

Choi, Young Lim ;

Kato, Motohiro ;

Ohira, Miki ;

Sanada, Masashi ;

Wang, Lili ;

Soda, Manabu ;

Kikuchi, Akira ;

Igarashi, Takashi ;

Nakagawara, Akira ;

Hayashi, Yasuhide ;

Mano, Hiroyuki ;

Ogawa, Seishi .

NATURE, 2008, 455 (7215) :971-U56

[4] Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer [J].

Choi, Young Lim ;

Takeuchi, Kengo ;

Soda, Manabu ;

Inamura, Kentaro ;

Togashi, Yuki ;

Hatano, Satoko ;

Enomoto, Munehiro ;

Hamada, Toru ;

Haruta, Hidenori ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Ueno, Toshihide ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Sugiyama, Yukihiko ;

Ishikawa, Yuichi ;

Mano, Hiroyuki .

CANCER RESEARCH, 2008, 68 (13) :4971-4976

[5] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[6] Strategies to overcome resistance to targeted protein kinase inhibitors [J].

Daub, H ;

Specht, K ;

Ullrich, A .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1001-1010

[7] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[8] Crizotinib in Anaplastic Large-Cell Lymphoma [J].

Gambacorti-Passerini, Carlo ;

Messa, Cristina ;

Pogliani, Enrico M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (08) :775-776

[9] Activating mutations in ALK provide a therapeutic target in neuroblastoma [J].

George, Rani E. ;

Sanda, Takaomi ;

Hanna, Megan ;

Frohling, Stefan ;

Luther, William, II ;

Zhang, Jianming ;

Ahn, Yebin ;

Zhou, Wenjun ;

London, Wendy B. ;

McGrady, Patrick ;

Xue, Liquan ;

Zozulya, Sergey ;

Gregor, Vlad E. ;

Webb, Thomas R. ;

Gray, Nathanael S. ;

Gilliland, D. Gary ;

Diller, Lisa ;

Greulich, Heidi ;

Morris, Stephan W. ;

Meyerson, Matthew ;

Look, A. Thomas .

NATURE, 2008, 455 (7215) :975-978

[10] Inflammatory myofibroblastic tumours: where are we now? [J].

Gleason, B. C. ;

Hornick, J. L. .

JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (04) :428-437

← 1 2 3 4 →